Supplemental Material Table of Contents

Supplemental Table 1: Items included in the CMS ESRD Prospective Payment System (Expanded Bundle) 1,2,3

Supplemental Table 2: Physician Monthly Capitated Payment (MCP) Requirements for CMS in the United States $^{\rm 1}$

Supplemental Table 1: Items included in the CMS ESRD Prospective Payment System (Expanded Bundle)^{1,2,3}

All items and services included prior to December 31, 2010, including but not limited to:

Supplies and equipment in the ESRD facility or patient home Capital-related costs to furnishing dialysis

Nursing and support services, including dieticians and social workers

Administrative and overhead costs

Drugs and biologicals for the treatment of ESRD, including but not limited to:

Erythropoietin stimulating agents

Vitamin D and its analogs

Calcimimetic therapy

Intravenous Iron therapy

Antibiotics

Diagnostic laboratory tests for the treatment of ESRD

The Prospective Payment System includes several adjustors:

Facility-level: Low volume, wage, and rural location

Patient-level: Age, BSA, low BMI, onset of dialysis, 4 comorbidity categories

Training add-on for home and self-dialysis modalities

- 1. Effective January 1, 2011, Section 1881(b)(14) of the Social Security Act required a bundled Prospective Payment System for renal dialysis services furnished to Medicare beneficiaries for the treatment of ESRD
- 2. https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ESRDpayment/index.html Accessed January 7, 2018
- 3. https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/downloads/bp102c11.pdf Accessed January 7, 2018
- 4. Effective January 1, 2018, injectable, intravenous, and oral calcimimetics qualify for the Transitional Drug Add-on Payment Adjustment (TDAPA) under the ESRD PPS.

CMS - Centers for Medicare & Medicaid Services

ESRD - End Stage Renal Disease

BSA - Body surface area

BMI – Body mass index

The 4 current comorbidities for patient-level adjustors are: Hereditary hemolytic or sickle cell anemia, Myelodysplastic syndrome, acute GI Bleed and acute pericarditis

Supplemental Table 2: Physician Monthly Capitated Payment (MCP) Requirements for CMS in the United States ¹

In-center hemodialysis: Frequency of face-to-face visits determines reimbursement

One per month

Two to three per month

Four or more per month

Home Dialysis: One monthly payment irrespective of frequency

Location: Dialysis clinic or physician office

Face-to-face in dialysis clinic once every three months

Comprehensive monthly visit includes assessment of:

Diet and nutrition

Suitability for dialysis modality

Dialysis Access

Candidacy for kidney transplantation

Dialysis prescription and adequacy

Anemia

Chronic kidney disease mineral and bone disorder

(CKD-MBD)

Dialysis related complications (e.g. neuropathy)

Volume status

Blood pressure control

Subsequent monthly visits include: one or more comprehensive monthly areas

Coordination with other professional staff, including dietitians and social workers

Periodic review and update of care plan

1- https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/downloads/clm104c08.pdf Accessed January 6, 2018

CMS - Centers for Medicare & Medicaid Services

The monthly home dialysis MCP is essentially equivalent to 2 to 3 visits in-center hemodialysis MCP. The Bipartisan Budget Act of 2018 expands telehealth coverage to patients on home dialysis by allowing the home to serve as an originating site. Reimbursement also varies, depending on geographic location. This table is relevant to CMS billing requirements, not Veterans Administration, Private Insurers, or Medicaid. Approximately 80% of patients receive payment for dialysis through Medicare in the United States. CMS will reimburse 80%, with the additional 20% being covered through supplemental insurance, out of pocket payment, or other mechanisms.